Sekundære effektparametre Intravenøs Bondronat 6 mg viste i sammenligning med placebo en statistisk signifikant forbedring i knoglesmertescore.
Secondary Efficacy Endpoints A statistically significant improvement in bone pain score was shown for intravenous Bondronat 6 mg compared to placebo.